Fig. 1: Global m6A levels are increased in PBMC of COVID-19 patients and showed differentially m6A-modified transcripts. | Cell Death & Disease

Fig. 1: Global m6A levels are increased in PBMC of COVID-19 patients and showed differentially m6A-modified transcripts.

From: RBM15-mediated N6-methyladenosine modification affects COVID-19 severity by regulating the expression of multitarget genes

Fig. 1

A Experimental design. B Volcano plot showing abnormally methylated mRNAs in group S (left) and M (right), as compared with group N (FC > 1.5, P < 0.05). C Volcano plots showing the correlation between log2 fold change (FC) of differentially expressed transcripts and log2 FC of differentially m6A-methylated transcripts in groups S and M in comparison with group N separately. D Volcano plots of log2 FC of differentially expressed transcripts and aberrantly methylated transcripts in group S in comparison with group M (left) and the figure on the right showed differentially genes only in group S compared with group N (color plots in four quadrants) but not in M compared with N (gray plots in four quadrants) (FC > 1.5, P < 0.05).

Back to article page